Celldex Therapeutics Inc. (CLDX)
Celldex Therapeutics Inc. (CLDX) Stock Price, Analysis & Data
| Бид | 36.43 |
| Рыночная капитализация | 3.28B |
| Выручка (TTM) | 158K |
| Чистая прибыль (TTM) | -300.55M |
| Бета | 0.84 |
| EPS (TTM) | -4.35 |
| P/E (TTM) | n/a |
| Прогнозный P/E | -10.04 |
| P/B (TTM) | 4.59 |
| P/S (TTM) | 20770.57 |
| Earnings Date | Nov 9, 2026 |
| Аск | 48.47 |
| Объём торгов | 249,041 |
| Ср. объём (20д) | 1,032,000 |
| Открытие | 42.51 |
| Пред. закрытие | 41.79 |
| Диапазон дня | 41.73 - 43.20 |
| Диапазон за 52 недели | 20.37 - 45.14 |
| Аналитики | n/a |
| Целевая цена | n/a |
| Дивиденды | n/a |
| Дата отсечки | n/a |
О компании CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...
Финансовые результаты
В 2025 году выручка Celldex Therapeutics составила 1.54M — это снижение на -77.99% к прошлогодним 7.02M. Прибыль составила -258.76M — это рост на 63.91%.
Финансовая отчётностьСюрприз в отчёте
Аналитики ждут выручку ... Улучшить тариф
1 неделю назад · Simply Wall St.
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter ResultsCelldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...
1 неделю назад · Simply Wall St.
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% ReturnCelldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...
1 неделю назад · Simply Wall St.
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...
